Results 131 to 140 of about 1,243,120 (289)

Room for improvement: Dr Gillian Shorter asks whether it is time to trial and evaluate an official ‘drug consumption room’, following another year of the highest overdose deaths on record [PDF]

, 2020
Gillian W. Shorter
openalex  

Assessment of reliability and validity of original questionnaire to evaluate knowledge of and attitudes towards extending professional powers of nurses and midwives with respect to independent prescription of certain drugs, writing out prescriptions, and referring for diagnostic tests – preliminary report [PDF]

, 2016
Mariusz Pańczyk, Aleksander Zarzeka, Lucyna Iwanow, Jarosława Belowska, Joanna Gotlib   +4 more
openalex   +1 more source

Development and Evaluation of Targeted Drug Delivery Systems of Tenoxicam TDDS Prepared With Solid Dispersions

, 2022
Dr. K. Satya Lakshmi
openalex   +2 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Live-cell imaging-based dynamic vascular formation assay for antivascular drug evaluation and screening. [PDF]

iScience, 2023
Li Z, Zhang H, Sun Y, Feng Z, Cui B, Han J, Li Y, Liu H, Sun T.   +8 more
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC

Frontiers in Pharmacology, 2021
Xiao Wang, Chao Liang, Xin Yao, Ruo-Han Yang, Zhan-Sheng Zhang, Fan-Ye Liu, Wen-Qi Li, Shu-Hua Pei, Jing Ma, Song-Qiang Xie, Song-Qiang Xie, Dong Fang   +11 more
doaj   +1 more source

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. [PDF]

Clin Cancer Res, 2023
Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.   +30 more
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Cancer Communications, 2023
Limin Zou, Yueli Qi, Yongling Jiang, Ling Tang, Yu Du, Boyuan Zhao, Yanzhe Sun, Meiyi Xiang, Jun Ma, Zhimin Yang   +9 more
doaj   +1 more source